论文部分内容阅读
目的 观察不同剂量的溴化异丙托品 (IPB)短时及长期应用 ,对稳定期慢性阻塞性肺疾病 (COPD)患者的肺功能及运动耐受性的影响。方法 37例稳定期COPD患者 ,随机分 3组 ,分别吸入IPB1 6 0 μg/次、80μg/次、40 μg/次。用药前后行肺功能及自行车功量仪极量运动负荷法运动试验测验。 结果 吸入IPB1 6 0 μg/次、80 μg/次组与安慰剂对照组相比 ,通气及运动指标均明显改善 (P <0 .0 1、P <0 .0 5 )。 40 μg/次组与安慰剂对照组相比 ,仅 1s量 (FEV1 )、每分最大通气量 (VEmax)改善 ,最大作功率 (Wmax)、每分最大摄氧量 (VO2 max)无明显改善。用药前后心率血压无明显变化。结论 溴化异丙托品可以改善通气 ,对气道阻塞的改善有量效关系。溴化异丙托品对心血管系统无明显影响
Objective To observe the effects of different doses of ipratropium bromide (IPB) on lung function and exercise tolerance in patients with stable chronic obstructive pulmonary disease (COPD) in short and long term. Methods Thirty-seven patients with stable COPD were randomly divided into 3 groups: IPB1 60 μg / time, 80 μg / time and 40 μg / time respectively. Before and after treatment of lung function and bicycle power meter extreme exercise load test exercise test. Results Compared with the placebo group, the inhalation of IPB1 at 60 μg / time and ventilation at 80 μg / time significantly improved the ventilation and exercise parameters (P <0.01, P <0.05). Compared with the placebo group, 40 μg / subgroup showed no significant improvement in FEV1, VEmax, Wmax and VO2 max . Heart rate before and after treatment no significant change in blood pressure. Conclusion ipratropium bromide can improve the ventilation, the improvement of airway obstruction has a dose-effect relationship. Ipratropium bromide has no significant effect on the cardiovascular system